RxDoctor Payments Data

David Boes, MD

Ophthalmology · Great Falls, MTNPI 1487655379

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 15 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Bausch & Lomb Americas Inc. accounts for 64.5% of it on its own, with 5 other manufacturers making up the rest.

$805in general payments, 2019–2025

Across 15 payments — averaging $53.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$519
  • AbbVie$119
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$61
  • Alcon$51
  • NEW World Medical,inc.$37
  • Biotissue Holdings Inc.$18

What the payments were for

  • Food & beverage$805100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$805 in reported general payments places this provider in the 65th percentile of 52 ophthalmology providers in Montana.

See all ophthalmology providers in Montana

Medicare billing

Part B allowed, 2024
$1,307,009
Medicare patients
1,571
Services billed
5,711

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate1,402$60,707
Tobramycin-DexamethasoneTobramycin/Dexamethasone1,280$45,431
Flurbiprofen Sodium1,328$45,302
RestasisCyclosporine15$23,780
Cyclosporine15$7,910
LumiganBimatoprost18$7,210
RhopressaNetarsudil Mesylate22$6,996
RocklatanNetarsudil Mesylat/Latanoprost15$5,227
Ketorolac Tromethamine169$4,404
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol17$2,709
SimbrinzaBrinzolamide/Brimonidine Tart13$2,689
Latanoprost131$1,297
ValacyclovirValacyclovir Hcl22$523
MoxifloxacinMoxifloxacin Hcl16$409
ErythromycinErythromycin Base15$164

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$119$30,99033 claims
AlconSimbrinza$51$2,68913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 52 ophthalmology providers in Montana.

Other ophthalmology in Great Falls

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →